Clinical trial
Phase I Single Arm, Dose Escalating and Phase II Double Blind, Randomized, Placebo-controlled, Dose Finding Clinical Trial Assessing Safety and Efficacy of Intratracheal Administration of Allogeneic Umbilical Cord Mesenchymal Cells-derived Extracellular Vesicles in Preventing Bronchopulmonary Dysplasia in Extremely Preterm Newborns
NCT06279741 is registered in ClinicalTrials.gov with EXO Biologics S.A. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase I Single Arm, Dose Escalating and Phase II Double Blind, Randomized, Placebo-controlled, Dose Finding Clinical Trial Assessing Safety and Efficacy of Intratracheal Administration of Allogeneic Umbilical Cord Mesenchymal Cells-derived Extracellular Vesicles in Preventing Bronchopulmonary Dysplasia in Extremely Preterm Newborns
- Lead sponsor
- EXO Biologics S.A.
- Phase
- Phase 1/2
- Overall status
- Recruiting
- Start date
- December 28, 2023
- Completion date
- December 31, 2029
- Enrollment
- 265 (estimated)
- Sites
- 8
Conditions
As the registry lists them; a condition with its own page is linked.